Turn Therapeutics Inc. Net Income
Turn Therapeutics Inc. (TTRX) reported Net Income of -$5.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-12
- Turn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$5.85M.
- Turn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$970.97K.
- Turn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $279.07K.
- Turn Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$1.90M.
- Turn Therapeutics Inc. net income (loss) attributable to parent for fiscal 2025 was -$3.19M.
- Turn Therapeutics Inc. net income (loss) attributable to parent for fiscal 2024 was -$1.77M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.85M 10-Q · filed 2026-08-12 | -$6.82M 10-Q · filed 2026-08-12 | -$6.54M derived: sum of 3 quarters · filed 2026-08-12 | -$8.45M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$970.97K 10-Q · filed 2026-05-11 | -$691.90K derived: sum of 2 quarters · filed 2026-05-11 | -$2.60M derived: sum of 3 quarters · filed 2026-05-11 | -$3.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $279.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.63M derived: sum of 2 quarters · filed 2026-03-31 | -$2.87M derived: sum of 3 quarters · filed 2026-08-12 | -$3.19M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$1.90M 10-Q · filed 2025-11-13 | -$3.14M derived: sum of 2 quarters · filed 2026-08-12 | -$3.47M 10-Q · filed 2025-11-13 | -$3.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$1.24M 10-Q · filed 2026-08-12 | -$1.57M 10-Q · filed 2026-08-12 | -$1.89M derived: sum of 3 quarters · filed 2026-08-12 | -$2.56M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$328.55K 10-Q · filed 2026-05-11 | -$651.68K derived: sum of 2 quarters · filed 2026-05-11 | -$1.32M derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$323.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$989.57K derived: sum of 2 quarters · filed 2026-03-31 | -$1.77M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$666.44K 10-Q · filed 2025-11-13 | -$1.45M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |